ArticleDie Naturwissenschaften2025
The oncogenic role of BCL2L12 associated with immune status in the prognosis of human hepatocellular carcinoma.
Article in Die Naturwissenschaften, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a global challenge with a high cancer-related death rate. Although BCL2L12 has been reported to be upregulated in mice with HCC, and its deletion markedly inhibits HCC progression, its specific role and associated tumorigenesis mechanisms in human HCC remain elusive. Differential gene expression analysis was performed using TCGA and GEPIA databases. Survival probability analysis was conducted using the Kaplan-Meier method. Immune checkpoint-related prognosis in HCC and their correlation with BCL2L12 were analyzed. The correlation between BCL2L12 and immune infiltration was investigated using the TIMER database. MEXPRESS and MethSurv were employed to display methylation of BCL2L12 and prognostic value. Upstream ncRNAs of BCL2L12 were predicted using starBase, String and TargetScan. Protein-protein interaction network involving BCL2L12 was constructed via String. Genes related to BCL2L12 in HCC were obtained from the LinkedOmics database. BCL2L12-targeted drugs for HCC were predicted via RNAactDrug, Enrichr, CTD, and NetworkAnalyst. BCL2L12 expression was upregulated and associated with poor prognosis in HCC. BCL2L12 showed significant co-occurrence with an immune checkpoint, namely TNFRSF4. BCL2L12 was significantly associated with immune infiltration in HCC. Cg03848533 methylation and CYTOR/MIR4435-2HG-has-miR-125b-5p axis regulated BCL2L12 expression and prognosis of HCC. BCL2L12 interacted with ZNF215 and PUSL1, all of which were independent risk factors for overall survival in patients with HCC. Panobinostat, Pirinixic acid, and Fluorouracil were predicted to be the potential BCL2L12-targeted drug for HCC. Our findings offer an understanding of the Oncogenic Role of BCL2L12 associated with immune status in the prognosis of HCC and provide potential strategies for currently limited treatment.
Indexed as
Identifiers
41296062What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.